Pharma-Bio Serv increased quarterly Revenue by approximately $0.4 million to $2.3 million and reported a $14 thousand net loss, an improvement of approximately $190 thousand. Investors also saw nine-month Net Income reach approximately $252 thousand, with the company citing improved financial performance and confidence heading into the final quarter.
Key Highlights
- Nine-month revenue reached approximately $7.3 million, up approximately $0.5 million from the corresponding period.
- Nine-month net income was approximately $252 thousand, an improvement of approximately $352 thousand.
- Chief Executive Officer Victor Sanchez said Pharma-Bio Serv remained confident it could build on the progress through the final quarter.
Pharma-Bio Serv, Inc. (OTC: PBSV) increased quarterly revenue by approximately $0.4 million to $2.3 million for the period ended July 31, 2026.
Nine-Month Revenue Reaches $7.3 Million
Revenue for the nine months ended July 31, 2026, was approximately $7.3 million, representing an increase of approximately $0.5 million from the same period last year. Pharma-Bio Serv recorded net income of approximately $252 thousand over the nine-month period, an improvement of approximately $352 thousand compared with the corresponding prior-year period. Its markets include Puerto Rico, the United States, Europe and Brazil.
Management Cites Progress Into Final Quarter
Chief Executive Officer Victor Sanchez said the quarterly results reflected client relationships and specialized regulatory and compliance capabilities. He said Pharma-Bio Serv had focused on markets where its expertise creates a Competitive Advantage and continued efforts to improve operating efficiency.
FAQs
Q: What were Pharma-Bio Serv’s quarterly results?
A: For the period ended July 31, 2026, Pharma-Bio Serv reported quarterly revenue of approximately $2.3 million. This represented an increase of approximately $0.4 million.
Q: Did Pharma-Bio Serv report a profit for the nine months?
A: Yes. Pharma-Bio Serv reported approximately $252 thousand in net income for the nine months ended July 31, 2026, an improvement of approximately $352 thousand from the corresponding prior-year period.
Q: What was Pharma-Bio Serv’s nine-month revenue?
A: Pharma-Bio Serv reported approximately $7.3 million in revenue for the nine months ended July 31, 2026. That amount represented an increase of approximately $0.5 million from the same period last year.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.